(NASDAQ: VKTX) Viking Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 56.37%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.57%.
Viking Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast VKTX's revenue for 2025 to be $2,807,738,625, with the lowest VKTX revenue forecast at $2,807,738,625, and the highest VKTX revenue forecast at $2,807,738,625. On average, 1 Wall Street analysts forecast VKTX's revenue for 2026 to be $1,123,095,450, with the lowest VKTX revenue forecast at $1,123,095,450, and the highest VKTX revenue forecast at $1,123,095,450.
In 2027, VKTX is forecast to generate $12,115,392,167 in revenue, with the lowest revenue forecast at $8,253,628,462 and the highest revenue forecast at $15,977,155,872.